{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Rheumatoid Arthritis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 18,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 18,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "122"
                        ],
                        "SecondaryIdDomain": [
                              "Council for Stem Cell Sciences and Technologies"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Grant/Funding Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03333681"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rheumatoid Factor, C-reactive protein"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RA Serology",
                              "Disease Activity Score (DAS 28) Index Mean Change From Baseline",
                              "Patient's assessment of pain."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 and 6 months",
                              "1, 3 and 6 months",
                              "1, 3 and 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01547091"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rheumatoid Factor, C-reactive protein"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RA Serology",
                              "Disease Activity Score (DAS 28) Index"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1, 3 ,6 and 12 months",
                              "1, 3, 6 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02643823"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Evaluation the resurfacing of articular cartilage after mesenchymal transplantation by MRI and radio logic assessment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Imaging"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://RoyanInstitute.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01873625"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with a change in disease activity index as measured by 28-DAS Score",
                              "Number of participants with a change in current disease activity as measured by EULAR Response Criteria",
                              "Change from baseline quality of life measure (based on Stanford HAQ)",
                              "Change from baseline C-reactive protein",
                              "Change from baseline erythrocyte sedimentation rate (ESR)",
                              "Change from baseline anti-citrulline antibody measure",
                              "Change from baseline rheumatoid factor (RF)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of participants achieving ACR20",
                              "Percentage of participants achieving ACR50",
                              "Percentage of participants achieving ACR70",
                              "Change from baseline of the disease activity score based on DAS28-CRP",
                              "Change from baseline of the disease activity score based on DAS28-ESR",
                              "EULAR response",
                              "Change from baseline of the health assessment questionnaire(HAQ) score",
                              "Change from baseline of the simplified disease activity index (SDAI) score",
                              "Change from baseline of the clinical disease activity index (CDAI) score",
                              "Change from baseline of TNF-\u03b1 level",
                              "Change from baseline of IL-6 level"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13",
                              "Up to day 28\u00b13"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The patients achieves 20%, 50%, or 70% remission according to American College of Rheumatology (ACR) criteria.",
                              "White blood cell count increases to the 3.5\u00d710^9/L and platelet count increases to 80\u00d710^ 9.",
                              "The HGB increases by 10 g compared to the baseline is considered improvement.",
                              "FVC increases by 0.5% and DLCO increases by 10% compared to baseline",
                              "The area change of image of lung."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.",
                              "White blood cell count and platelet count improved compared to the baseline.",
                              "Improvement rate of blood routine hemoglobin (HGB) compared to baseline.",
                              "Improvement rate of forced vital capacity (FVC) and/or carbon monoxide",
                              "Image improvement of lung on high resolution CT.",
                              "Improvement of 6-minute walking distance compared to baseline."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks and 24 weeks",
                              "12 weeks and 24 weeks",
                              "12 weeks",
                              "12 weeks",
                              "24 weeks",
                              "12 weeks and 24 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03798028"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [
                              "August 19, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "February 24, 2022"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Tumor Necrosis factor (TNF-a) (pg/mL) measured during trial.",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of interleukin 6 (IL-6) (pg/mL) during the trial",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of C-reactive protein (CRP) (mg/L) during the trial",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of erythrosedimentation rate (ESR) (mm/hr) during the trial.",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Joint Count 66/68 (# joints - tender and swollen) during the trial."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "DAS 28 is used to determine the disease activity for RA. It will be completed for each follow up point.",
                              "VAS is a scale that is used to measure pain. It will be completed for each follow up point."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy: the 28-joint disease activity score (DAS 28)",
                              "Efficacy: visual analog scale (VAS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Four year follow-up",
                              "Four year follow-up"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05003934"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The ACR70 is a composite measure defined as both improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).",
                              "The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of <3.2 suggests a low level of disease activity, while a score of >5.1 suggests a high level of disease activity.",
                              "The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty when performing daily activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3).",
                              "The SDAI is the numerical sum of five outcome parameters: tender joint count and swollen joint count based on a 28-joint assessment, patient global health assessment and physician global health assessment (from 0=best to 10=worst), and C-reactive protein (CRP). SDAI total score= 0 to 86. SDAI <=3.3 indicates disease remission, >3.3 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high disease activity.",
                              "Rheumatoid factor blood test result.",
                              "Anti-CCP blood test result."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24",
                              "Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24",
                              "Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24",
                              "Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24",
                              "Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24",
                              "Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24",
                              "Change from Baseline of rheumatoid factor at Week 12 and Week 24",
                              "Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion",
                              "12 weeks and 24 weeks after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "R21AR069226"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/R21AR069226"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "2. Change in patient reported outcomes (PROMIS CAT and legacy [RAPID 3 / SF36] -questionnaires)",
                              "Changes in DAS28-CRP"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in patient reported outcomes",
                              "DAS28-CRP"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to day 28 after infusion",
                              "Week 52"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03186417"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Proportion of ACR 20 patients (swollen joints, tender joints, patient assessment of pain, RAPID3, DAS28-CRP and blood inflammatory panel tests) in comparison between baseline and post-treatment follow-up data."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy of Celltex AdMSCs"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04170426"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of the Physical Activity measure by WOMAC scoring",
                              "Evaluation the resurfacing of articular cartilage by MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "1 month",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03067870"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "DAS range is from \u2265 3.2 (inactive) , >3.2 but \u2264 5.1(moderate), >5.1(very active)",
                              "KHAQ range is from 0 (clear) to 60 (severe)",
                              "CDAI range is from 0 (clear) to 76 (severe)",
                              "100mm Pain VAS range is from 0 (clear) to 100 (severe)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate",
                              "Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate",
                              "Efficacy as measured by DAS(Disease activity scores)28-ESR",
                              "Efficacy as measured by KHAQ(Korean Health assessment questionnaire)",
                              "Efficacy as measured by CDAI (clinical disease activity index)",
                              "Efficacy as measured by 100mm Pain VAS(Visual analogue scale)",
                              "Total number of use and consumed amount of rescue medicine",
                              "Change in Cytokine(TNF-a, Interleukin (IL)-1b, IL-4,IL-6,IL-8,IL-10,IL-13,IL-17A,IL-21,IL-22)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment",
                              "16 weeks follow-up after treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03618784"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "clinical symptoms including fatigue (Fatigue Impact Score, FIS) and pruritus ( Visual Analog Scale ,VAS)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Histological changes in liver biopsies",
                              "Serum Bilirubin",
                              "Serum AST",
                              "Mayo risk score",
                              "Number of patients with Portal Hypertension after 12 weeks treatment",
                              "MELD score",
                              "Number of participants with improvement of clinical symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and 48 weeks",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48",
                              "At base line and at week 4,8,12,24,36 and 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "weight gain, acne, facial rounding, dorsal hump formation, hirsutism, osteopenia and diabetes mellitus, et al",
                              "diffuse arthralgias, fatigue, generalized malaise, jaundice, abdominal pain, nausea, and loss of appetite"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serum AST",
                              "Serum Tbil",
                              "Serum immunoglobulin G (IgG)",
                              "Serum \u03b3-globulin",
                              "MELD score",
                              "Number of participants with treatment side effects",
                              "Number of participants with improvement of clinical symptoms"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At baseline and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96",
                              "At base line and at week 12, 24, 36, 48, 72, 96"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01661842"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient\u00b4s assessment of pain ***, ESR/CRP, HAQ score)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At selection and screening visit, and once per month during 6 months after the last administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01663116"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Radiographic outcome assessments",
                              "FFI-R, SF-12",
                              "AOFAS"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Radiographic outcome assessments",
                              "Functional outcome measurements",
                              "Functional outcome measurements"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Pre-operatively, 6 weeks, 3, 6, 12 and 24 months",
                              "Pre-operatively, 6 weeks, 3, 6, 12 and 24 months",
                              "Pre-operatively, 3, 6, 12 and 24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01413061"
                        ]
                  }
            ]
      }
}